Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment

Transplantation

Volumn 98, Issue 9, 2014, Pages 1013-1018

  Stern, Martin ^a   Hirsch, Hans ^a,b   Cusini, Alexia ^c   Van Delden, Christian ^d   Manuel, Oriol ^e   Meylan, Pascal ^e   Boggian, Katia ^f   Mueller, Nicolas J ^g   Dickenmann, Michael ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY HOSPITAL   (Switzerland)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f Kantonsspital St Gallen   (Switzerland)

^g PSI   (Switzerland)

Author keywords

CMV; Infection; Organ transplantation; Rejection

Indexed keywords

CYCLOSPORIN; MYCOPHENOLIC ACID; PREDNISONE; TACROLIMUS; VALGANCICLOVIR; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; BIOPSY; CHILD; COHORT ANALYSIS; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT REJECTION; HEART TRANSPLANTATION; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INFANT; INFECTION PREVENTION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEWBORN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SERODIAGNOSIS; SWITZERLAND; VIRUS REPLICATION; BLOOD; CLINICAL TRIAL; CYTOMEGALOVIRUS; GRAFT SURVIVAL; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; PRESCHOOL CHILD; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOPSY; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; INFANT, NEWBORN; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SWITZERLAND; TREATMENT OUTCOME; VIRUS REPLICATION; YOUNG ADULT;

EID: 84925021519     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000160     Document Type: Article

References (22)

1. Humar A, Snydman D. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009; 9(suppl 4): S78.
2. Kute VB, Vanikar AV, Shah PR, et al. Post-renal transplant cytomeg-alovirus infection: study of risk factors. Transplant Proc 2012; 44: 706.
3. Cook CH, Bickerstaff AA, Wang JJ, et al. Disruption of murine cardiac allograft acceptance by latent cytomegalovirus. Am J Transplant 2009; 9: 42.
4. Toupance O, Bouedjoro-Camus MC, Carquin J, et al. Cytomegalovirus-related disease and risk of acute rejection in renal transplant recipients: a cohort study with case-control analyses. Transplant Int 2000; 13: 413.
5. Arthurs SK, Eid AJ, Pedersen RA, et al. Delayed-onset primary cyto-megalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008; 46: 840.
6. Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999; 340: 1462.
7. Nett PC, Heisey DM, Fernandez LA, et al. Association of cytomega-lovirus disease and acute rejection with graft loss in kidney transplantation. Transplantation 2004; 78: 1036.
8. Danziger-Isakov LA, DelaMorena M, Hayashi RJ, et al. Cytomegalo-virus viremia associated with death or retransplantation in pediatric lung-transplant recipients. Transplantation 2003; 75: 1538.
9. Potena L, Valantine HA. Cytomegalovirus-associated allograft rejection in heart transplant patients. Curr Opin Infect Dis 2007; 20: 425.
10. Slifkin M, Ruthazer R, Freeman R, et al. Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation. Liver Transplant 2005; 11: 1597.
11. Manuel O, Kralidis G, Mueller NJ, et al. Impact of antiviral preventive strategies on the incidence and outcomes of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2013; 13: 2402.
12. Uknis ME. Prophylaxis of cytomegalovirus disease in transplant patients. Am J Health Syst Pharm 2005; 62(8 suppl 1): S3.
13. Manuel O, Kumar D, Moussa G, et al. Lack of association between beta-herpesvirus infection and bronchiolitis obliterans syndrome in lung transplant recipients in the era of antiviral prophylaxis. Transplantation 2009; 87: 719.
14. Abou-Ayache R, Buchler M, Le Pogamp P, et al. The influence of cy-tomegalovirus infections on patient and renal graft outcome: a 3-year, multicenter, observational study (Post-ECTAZ Study). Transplant Proc 2011; 43: 2630.
15. Jaksch P, Zweytick B, Kerschner H, et al. Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3-vs 12-month valganciclovir therapy. J Heart Lung Transplant 2009; 28: 670.
16. Palmer SM, Limaye AP, Banks M, et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med 2010; 152: 761.
17. Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10: 1228.
18. Koller MT, van Delden C, Muller NJ, et al. Design and methodology of the Swiss Transplant Cohort Study (STCS): a comprehensive prospective nationwide long-term follow-up cohort. Eur J Epidemiol 2013; 28: 347.
19. Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005; 24: 1710.
20. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8: 753.
21. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997; 25: 658.
22. Stewart S, Fishbein MC, Snell GI, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant 2007; 26: 1229.